Gyroscope board fortified by trio of life science stars
Gyroscope Therapeutics, the Stevenage based clinical-stage retinal gene therapy company, has strengthened its board with three appointments. Jennifer Cook, David Fellows, and Renée Galá have been appointed.
Cook was most recently CEO of GRAIL, a healthcare company focused on the early detection of cancer. Prior to joining GRAIL, she held a number of leadership positions during her 25-year tenure with Roche/Genentech, including leading Roche Pharmaceuticals’ European commercial business, Global Clinical Operations, US and Global Product Portfolio Management, the U.S. Immunology and Ophthalmology Business Unit, and market development.
She currently serves on the boards of Denali Therapeutics, BridgeBio Pharma, and Ambys Medicines.
Fellows was most recently the CEO of Nightstar Therapeutics, a retinal gene therapy company acquired by Biogen in 2019. Prior to joining Nightstar, he was the VP of Johnson & Johnson’s Vision Care Franchise.
Before joining Johnson & Johnson, Fellows held leadership positions at Allergan, Inc., for 25 years where he served primarily in sales and marketing in a number of capacities.
Galá currently serves as the executive vice-President and CFO of Jazz Pharmaceuticals, a global biopharmaceutical company. Prior to joining Jazz, she served as the CFO of GRAIL.